CDXS - NASDAQ
Codexis, Inc.
$2.69
+1.1%Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotcdxs
Research Development Expenses
Last Annual Value
44.36M
3-Year CAGR
-18%
5-Year CAGR
%
10-Year CAGR
8%
Codexis, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Codexis, Inc. NASDAQ:CDXS | 44.36M | -9.0% | -4.5% | 7.2% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 104.24M | -4.0% | 1.9% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 47.75M | -5.5% | 4.0% | N/A | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 70.09M | 31.0% | 14.0% | 16.3% | |
 Immuneering Corporation NASDAQ:IMRX | 42.05M | 0.3% | 9.6% | N/A | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 58.19M | 19.8% | 35.2% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 73.70M | 14.1% | 7.6% | N/A | |
 Rani Therapeutics Holdings, Inc. NASDAQ:RANI | 20.20M | -20.1% | -5.3% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 23.72M | -11.1% | 3.5% | 15.4% | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 42.63M | 19.8% | 15.1% | 8.5% | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 15.90M | 19.6% | 25.9% | 10.8% |
Codexis, Inc. Fair Value Envelope
Related Guides
Continue your CDXS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.